S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
pixel
pixel
S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
pixel
pixel
S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
pixel
pixel
S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
pixel
pixel
Log in
NASDAQ:CLGN

CollPlant Biotechnologies Stock Forecast, Price & News

$14.80
-0.10 (-0.67 %)
(As of 01/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$14.54
Now: $14.80
$15.00
50-Day Range
$8.38
MA: $11.66
$15.76
52-Week Range
$6.00
Now: $14.80
$16.32
Volume9,519 shs
Average Volume34,382 shs
Market Capitalization$83.92 million
P/E RatioN/A
Dividend YieldN/A
Beta1.11
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bio-printing of tissues and organs, and medical aesthetics in the United States, Canada, and Europe. The company's products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. Its products include BioInks for 3D printing of tissues and organs; dermal filler for treating wrinkles; 3D Bioprinted breast implants; VergenixSTR, a soft tissue repair matrix intended for treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. CollPlant Biotechnologies Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.

MarketRank

Overall MarketRank

0.74 out of 5 stars

Medical Sector

1163rd out of 1,925 stocks

Surgical Appliances & Supplies Industry

30th out of 40 stocks

Analyst Opinion: 1.5Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CLGN
CUSIPN/A
CIKN/A
Phone972-73-232-5600
Employees38
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.32 million
Book Value$0.72 per share

Profitability

Net Income$-11,160,000.00
Net Margins-149.91%

Miscellaneous

Market Cap$83.92 million
Next Earnings Date4/7/2021 (Estimated)
OptionableNot Optionable
$14.80
-0.10 (-0.67 %)
(As of 01/26/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CLGN News and Ratings via Email

Sign-up to receive the latest news and ratings for CLGN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











CollPlant Biotechnologies (NASDAQ:CLGN) Frequently Asked Questions

How has CollPlant Biotechnologies' stock been impacted by Coronavirus?

CollPlant Biotechnologies' stock was trading at $10.20 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CLGN shares have increased by 45.1% and is now trading at $14.80.
View which stocks have been most impacted by COVID-19
.

Is CollPlant Biotechnologies a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CollPlant Biotechnologies in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CollPlant Biotechnologies stock.
View analyst ratings for CollPlant Biotechnologies
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than CollPlant Biotechnologies?

Wall Street analysts have given CollPlant Biotechnologies a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but CollPlant Biotechnologies wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is CollPlant Biotechnologies' next earnings date?

CollPlant Biotechnologies is scheduled to release its next quarterly earnings announcement on Wednesday, April 7th 2021.
View our earnings forecast for CollPlant Biotechnologies
.

How were CollPlant Biotechnologies' earnings last quarter?

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) issued its quarterly earnings data on Monday, November, 30th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.92 by $0.85. The firm had revenue of $4.15 million for the quarter, compared to analysts' expectations of $11.74 million. CollPlant Biotechnologies had a negative trailing twelve-month return on equity of 116.41% and a negative net margin of 149.91%.
View CollPlant Biotechnologies' earnings history
.

What price target have analysts set for CLGN?

1 brokerages have issued 1 year price targets for CollPlant Biotechnologies' stock. Their forecasts range from $13.00 to $13.00. On average, they expect CollPlant Biotechnologies' stock price to reach $13.00 in the next year. This suggests that the stock has a possible downside of 12.2%.
View analysts' price targets for CollPlant Biotechnologies
or view Wall Street analyst' top-rated stocks.

Who are some of CollPlant Biotechnologies' key competitors?

What other stocks do shareholders of CollPlant Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CollPlant Biotechnologies investors own include Genocea Biosciences (GNCA), Boingo Wireless (WIFI), Allena Pharmaceuticals (ALNA), Advanced Micro Devices (AMD), Ampio Pharmaceuticals (AMPE), Energy Transfer (ET), HTG Molecular Diagnostics (HTGM), OPKO Health (OPK), Ovid Therapeutics (OVID) and (PRMW).

Who are CollPlant Biotechnologies' key executives?

CollPlant Biotechnologies' management team includes the following people:
  • Mr. Yehiel Tal, Chief Exec. Officer (Age 69, Pay $495k)
  • Mr. Eran Rotem CPA, Deputy CEO & CFO (Age 53, Pay $311k)
  • Dr. Ilana Belzer, Chief Operations Officer (Age 61, Pay $242k)
  • Prof. Oded Shoseyov, Founder & Chief Scientist (Age 65)

When did CollPlant Biotechnologies IPO?

(CLGN) raised $22 million in an IPO on Friday, December 9th 2016. The company issued 3,500,000 shares at a price of $6.23 per share. Ladenburg Thalmann acted as the underwriter for the IPO and Roth Capital Partners was co-manager.

What is CollPlant Biotechnologies' stock symbol?

CollPlant Biotechnologies trades on the NASDAQ under the ticker symbol "CLGN."

Who are CollPlant Biotechnologies' major shareholders?

CollPlant Biotechnologies' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Villere ST Denis J & Co. LLC (1.55%).

Which institutional investors are buying CollPlant Biotechnologies stock?

CLGN stock was acquired by a variety of institutional investors in the last quarter, including Villere ST Denis J & Co. LLC.

How do I buy shares of CollPlant Biotechnologies?

Shares of CLGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is CollPlant Biotechnologies' stock price today?

One share of CLGN stock can currently be purchased for approximately $14.80.

How big of a company is CollPlant Biotechnologies?

CollPlant Biotechnologies has a market capitalization of $83.92 million and generates $2.32 million in revenue each year. The company earns $-11,160,000.00 in net income (profit) each year or ($1.29) on an earnings per share basis. CollPlant Biotechnologies employs 38 workers across the globe.

What is CollPlant Biotechnologies' official website?

The official website for CollPlant Biotechnologies is www.collplant.com.

How can I contact CollPlant Biotechnologies?

CollPlant Biotechnologies' mailing address is 4 OPPENHEIMER ST. 11TH FLOOR, REHOVOT L3, 74140. The company can be reached via phone at 972-73-232-5600 or via email at [email protected]

This page was last updated on 1/27/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.